Comparative Pharmacology
Head-to-head clinical analysis: NELARABINE versus TRABECTEDIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NELARABINE versus TRABECTEDIN.
NELARABINE vs TRABECTEDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nelarabine is a prodrug of ara-G, a deoxyguanosine analog. It is converted to ara-GTP, which accumulates in T-cells and inhibits DNA synthesis, leading to cell death.
Trabectedin binds to the minor groove of DNA, forming adducts that lead to DNA strand breaks and inhibition of transcription. It also affects the tumor microenvironment by modulating cytokine production and inhibiting activated macrophages.
1500 mg/m2 intravenously over 2 hours on days 1, 3, and 5, repeated every 28 days.
1.5 mg/m² intravenously over 24 hours every 3 weeks.
None Documented
None Documented
Terminal t1/2: 30 hours (range 21-48 h) in adults; prolonged in renal impairment. Ara-G (active metabolite) t1/2: 3 hours.
Clinical Note
moderateNelarabine + Digoxin
"Nelarabine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateTrabectedin + Digoxin
"Trabectedin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateNelarabine + Digitoxin
"Nelarabine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateTrabectedin + Digitoxin
"Trabectedin may decrease the cardiotoxic activities of Digitoxin."
Terminal elimination half-life ranges from 26 to 40 hours (mean ~33 hours) in patients with normal hepatic function, allowing for a 3-weekly dosing interval.
Renal: 50-60% as unchanged ara-G; fecal: <5% as metabolites; biliary: negligible.
Primarily fecal (approximately 58% of administered dose) with minor renal excretion (about 21% as unchanged drug and metabolites). Biliary excretion accounts for a significant portion of elimination via feces.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent